FORM 10-Q

                          SECURITIES AND EXCHANGE COMMISSION
                                Washington, DC  20549

(Mark One)
[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF
              THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended         March 31, 1996
                                -------------------------------------------
                                          OR

[  ]     TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF
              THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from _________________________ to _______________

Commission file number 0-19059

                             Deprenyl Animal Health, Inc.
                (Exact name of registrant as specified in its charter)

                Missouri                               36-3716293
      (State or other jurisdiction of                (I.R.S. Employer
     incorporation or organization)                Identification No.)

                               10955 Lowell, Suite 710
                             Overland Park, Kansas  66210
                       (address of principal executive offices)
                                      (Zip Code)

                                    (913) 338-2120
                 (Registrant's telephone number, including area code)


     Indicate by check mark whether the registrant  (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter period that the
registrant was required to file such reports), and (2) has been subject to such
filing requirements for the past 90 days.

                    Yes       x         No
                         ---------         ----------

                  APPLICABLE ONLY TO ISSUERS INVOLVED IN BANKRUPTCY
                     PROCEEDINGS DURING THE PRECEDING FIVE YEARS:

     Indicate by check mark whether the registrant has filed all documents and
reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 subsequent to the distribution of securities under a plan confirmed
by a court.

                    Yes            No
                          -----         -----

                        APPLICABLE ONLY TO CORPORATE ISSUERS:

Indicate the number of shares outstanding of each of the issuer's classes of
common stock, as of the latest practicable date.

                      7,510,998 common shares as of May 8, 1996




                          PART II. - OTHER INFORMATION

ITEM 6. Exhibit 27 - Financial Data Schedule.



                                      SIGNATURES


    Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.


                             DEPRENYL ANIMAL HEALTH, INC.


Date  May 10, 1996            By: /s/ David R. Stevens
                                 ------------------------------------
                             David R. Stevens
                             President, Chief Executive Officer, and
                             Chief Financial Officer